Atlantic Healthcare, a specialist gastrointestinal (GI) pharmaceutical company developing treatments for inflammatory bowel disease and other GI diseases, has appointed John Temperato as US president and COO, to lead the commercialisation programme of alicaforsen in the U.S.
Atlantic is developing alicaforsen for the treatment of inflammatory bowel disease (IBD). Results of the Phase 3 trial for alicaforsen enema in the treatment of orphan-designated IBD pouchitis are expected in Q1 2019.
John has a wealth of experience in pharmaceutical sales and marketing. He joins Atlantic Healthcare from Melinta Therapeutics where he was president and chief operating officer / chief commercial officer responsible for the commercialisation strategy and building the Company’s product portfolio.
